AZIENDA OSPEDALIERA UNIV SENESE has a total of 15 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2012. It filed its patents most often in EPO (European Patent Office), Australia and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are VIVOLUX AB, ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD and LOHOCLA RES CORPORATION.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | Australia | 2 | |
#3 | United States | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 | |
#7 | China | 1 | |
#8 | Italy | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Audio-visual technology | |
#5 | Medical technology | |
#6 | Basic materials chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Botta Maurizio | 9 |
#2 | Brai Annalaura | 9 |
#3 | Tintori Cristina | 9 |
#4 | Maga Giovanni | 4 |
#5 | Fazi Roberta | 4 |
#6 | Meyerhans Andreas | 4 |
#7 | Martinez Javier | 4 |
#8 | Martinez De La Sierra Miguel-Angel | 3 |
#9 | Sigalotti Luca | 2 |
#10 | Araque José-Esté | 2 |
Publication | Filing date | Title |
---|---|---|
CA3073652A1 | An electromechanical stimulation system for treating a tinnitus disease | |
WO2017162834A1 | Use of ddx3 inhibitors as antiproliferative agents | |
BR112017017229A2 | compound, compound for medical use or in the preparation of a medicament and pharmaceutical composition | |
EP3188596A1 | Human dermis, preparation and use thereof | |
EP2670861A2 | Markers of melanoma and uses thereof |